NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Open in Screener

AXON

Axon Enterprise Inc

May 06 • 04:00PM ET

601.67

Dollar change -19.73
Percentage change -3.18	%

Industrials • Aerospace & Defense • USA • NASD

Peers: KTOS SWBI VSTO DGLY NPK SPWH ADI DLTH

| Held by: VTI VOO QQQ VO SPY IVV VUG ITA VOT IWP

Index	NDX, S&P 500	P/E	125.91	EPS (ttm)	4.78	Insider Own	5.52%	Shs Outstand	76.62M	Perf Week	-1.55%
Market Cap	46.84B	Forward P/E	81.23	EPS next Y	7.41	Insider Trans	-2.44%	Shs Float	73.55M	Perf Month	21.03%
Income	376.22M	PEG	9.43	EPS next Q	1.27	Inst Own	79.85%	Short Float	1.98%	Perf Quarter	-9.24%
Sales	2.08B	P/S	22.47	EPS this Y	1.98%	Inst Trans	-0.82%	Short Ratio	1.78	Perf Half Y	42.07%
Book/sh	30.38	P/B	19.81	EPS next Y	22.27%	ROA	9.51%	Short Interest	1.45M	Perf Year	89.95%
Cash/sh	12.82	P/C	46.93	EPS next 5Y	13.35%	ROE	19.10%	52W Range	273.52 - 715.99	Perf YTD	1.24%
Dividend Est.	-	P/FCF	142.14	EPS past 5Y	218.25%	ROI	12.34%	52W High	-15.97%	Beta	1.25
Dividend TTM	-	Quick Ratio	2.04	Sales past 5Y	31.50%	Gross Margin	59.51%	52W Low	119.97%	ATR (14)	23.82
Dividend Ex-Date	-	Current Ratio	2.30	EPS Y/Y TTM	111.64%	Oper. Margin	2.82%	RSI (14)	55.97	Volatility	2.70% 4.42%
Employees	4100	Debt/Eq	0.31	Sales Y/Y TTM	33.32%	Profit Margin	18.05%	Recom	1.56	Target Price	674.69
Option/Short	Yes / Yes	LT Debt/Eq	0.31	EPS Q/Q	122.28%	Payout	0.00%	Rel Volume	0.92	Prev Close	621.40
Sales Surprise	1.61%	EPS Surprise	48.16%	Sales Q/Q	33.09%	Earnings	May 07 AMC	Avg Volume	819.37K	Price	601.67
SMA20	3.42%	SMA50	8.20%	SMA200	17.56%	Trades		Volume	754,900	Change	-3.18%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-20-25	Downgrade	Craig Hallum	Buy → Hold	$625
Feb-19-25	Downgrade	Northcoast	Buy → Neutral
Jan-08-25	Initiated	TD Cowen	Buy	$700
Dec-03-24	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$500 → $700
Sep-12-24	Reiterated	JMP Securities	Mkt Outperform	$375 → $430
Jul-17-24	Initiated	Jefferies	Buy	$385
Jul-17-24	Initiated	BofA Securities	Buy	$380
Apr-10-24	Reiterated	Needham	Buy	$315 → $400
Mar-13-24	Initiated	Argus	Buy	$380
Aug-22-23	Initiated	Morgan Stanley	Equal-Weight	$230
Jul-05-23	Resumed	JP Morgan	Overweight	$236
May-11-23	Upgrade	JP Morgan	Neutral → Overweight	$236
Mar-08-23	Initiated	Goldman	Buy	$263
Mar-02-23	Downgrade	JP Morgan	Overweight → Neutral	$224
Feb-17-23	Downgrade	Raymond James	Strong Buy → Outperform	$223
Sep-15-22	Initiated	Barclays	Overweight	$147
May-23-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight	$120
May-10-22	Initiated	Credit Suisse	Outperform	$169
Feb-25-22	Upgrade	JP Morgan	Neutral → Overweight	$222 → $192
Dec-14-21	Resumed	JMP Securities	Mkt Outperform	$195

Show Previous Ratings

Today 10:58AM	Will Segmental Sales Boost Kratos Defense in Q1 Earnings? (Zacks)
09:06AM	Sonos Gearing Up to Report Q2 Earnings: Here's What to Expect (Zacks)
08:00AM	3 Stocks That Turned a $15,000 Investment Into Over $1 Million in 15 Years (Motley Fool)
07:21AM	TOST Set to Release Q1 Earnings: Essential Insights for Investors (Zacks)
May-05-25 09:05AM	Leidos Holdings to Report Q1 Earnings: What's in the Cards? (Zacks)
09:02AM	Loading…
09:02AM	Axon Enterprise Gears Up to Post Q1 Earnings: Is a Beat in Store? (Zacks)
08:14AM	Flex Gearing Up to Report Q4 Earnings: Here's What to Expect (Zacks)
May-02-25 02:00PM	These 7 Stocks Are Analyst Favorites For Magnificent Earnings Growth; Two Top Buy Point (Investor's Business Daily)
09:30AM	Is It Worth Investing in Axon (AXON) Based on Wall Street's Bullish Views? (Zacks)
09:15AM	Unlocking Q1 Potential of Axon (AXON): Exploring Wall Street Estimates for Key Metrics (Zacks)
08:44AM	Will Solid Segmental Sales Boost TransDigm's Q2 Earnings? (Zacks)
08:33AM	BWX Technologies to Report Q1 Earnings: What's in Store for the Stock? (Zacks)
08:00AM	How To Trade Stocks, Like Market Leader Axon, During Earnings Season (Investor's Business Daily)
May-01-25 05:50PM	Axon Enterprise (AXON) Beats Stock Market Upswing: What Investors Need to Know (Zacks)
Apr-30-25 12:08PM	Will Poor Margin Performance Impact HII's Q1 Earnings? (Zacks)
10:01AM	Loading…
10:01AM	Axon Enterprise (AXON) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Apr-29-25 10:07AM	Will Segmental Revenues Bolster FTAI Aviation's Q1 Earnings? (Zacks)
09:30AM	Why This 1 Aerospace Stock Could Be a Great Addition to Your Portfolio (Zacks)
09:00AM	Investors Heavily Search Axon Enterprise, Inc (AXON): Here is What You Need to Know (Zacks)
08:30AM	Here's How Much You'd Have If You Invested $1000 in Axon Enterprise a Decade Ago (Zacks)
03:52AM	2 Tech Stocks That Could Help Make You a Fortune (Motley Fool)
Apr-28-25 06:00PM	Axon Enterprise (AXON) Stock Falls Amid Market Uptick: What Investors Need to Know (Zacks)
02:20PM	DroneShield Has A Niche Defense Market To Capitalize On (Seeking Alpha)
12:23PM	Best Defense Stocks in 2025... So Far (MarketBeat)
08:50AM	Want Better Returns? Don?t Ignore These 2 Aerospace Stocks Set to Beat Earnings (Zacks)
07:45AM	3 Super Stocks to Buy and Hold for the Next 10 Years (Motley Fool)
Apr-27-25 03:30PM	Axon Enterprise, Inc. (AXON): Among Stocks with Consistent Growth to Buy Now (Insider Monkey)
Apr-26-25 02:28PM	2 Growth Stocks to Buy on the Dip if the Market Crashes Again (Motley Fool)
Apr-24-25 04:13PM	Axon to Release First Quarter 2025 Earnings on May 7, 2025 (PR Newswire)
09:07AM	1 Profitable Stock to Target This Week and 2 to Steer Clear Of (StockStory)
06:25AM	Loading…
06:25AM	Why Is Everyone Talking About Axon Enterprise Stock? (Motley Fool)
Apr-23-25 12:10PM	Will Axon (AXON) Beat Estimates Again in Its Next Earnings Report? (Zacks)
09:05AM	The Ithaka Group Q1 2025 Commentary (Seeking Alpha)
Apr-22-25 06:51PM	Axon Enterprise, Inc. (AXON): One of the Top Defense Stock Picks from the Goldman Sachs Portfolio (Insider Monkey)
12:00PM	Axon Announces New Fixed ALPR Camera Solutions and Next-Gen AI Advancements to Expand Real-Time Public Safety Ecosystem (PR Newswire)
Apr-20-25 05:52AM	Axon Enterprise: Strong Moat And Long Term Growth Support Hold, Despite High Valuation (Seeking Alpha)
Apr-19-25 02:00PM	Think It's Too Late to Buy Axon Enterprise Stock? Here's Why There's Still Time. (Motley Fool)
Apr-18-25 03:29PM	Jim Cramer Cheers for Axon Enterprise (AXON): It's Not Just a Taser Anymore It's the Gold Standard! (Insider Monkey)
Apr-17-25 11:20AM	I Wouldn't Touch Axon Stock With A 10-Foot Pole (Technical Analysis) (Seeking Alpha)
Apr-16-25 06:00PM	Axon Enterprise (AXON) Stock Moves -1.03%: What You Should Know (Zacks)
09:30AM	Is Axon (AXON) a Buy as Wall Street Analysts Look Optimistic? (Zacks)
09:00AM	Here is What to Know Beyond Why Axon Enterprise, Inc (AXON) is a Trending Stock (Zacks)
08:00AM	Axon Stock: Three Telltale Clues In Focus As Taser Maker Regroups (Investor's Business Daily)
Apr-13-25 05:10AM	Could Axon Enterprise Help You Become a Millionaire? (Motley Fool)
Apr-10-25 05:50PM	Axon Enterprise (AXON) Stock Moves -1.53%: What You Should Know (Zacks)
09:45AM	BWX (BWXT) Surges 11.7%: Is This an Indication of Further Gains? (Zacks)
Apr-08-25 06:15PM	Is Axon Enterprise, Inc. (AXON) Among Defense Stocks with the Highest EPS Growth in 5 Years? (Insider Monkey) +11.07%
06:00PM	Axon Enterprise (AXON) Gains As Market Dips: What You Should Know (Zacks)
Apr-02-25 09:00AM	Axon Enterprise, Inc (AXON) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Apr-01-25 08:49AM	What Makes Axon Enterprise (AXON) an Attractive Bet? (Insider Monkey)
Mar-31-25 09:30AM	Brokers Suggest Investing in Axon (AXON): Read This Before Placing a Bet (Zacks)
Mar-30-25 06:11PM	The MaM Portfolio: 2025 Q1 Update (Seeking Alpha)
Mar-29-25 08:38AM	Axon Is Building God's Eye (Seeking Alpha)
Mar-28-25 11:30AM	Why Is Kratos (KTOS) Up 19.8% Since Last Earnings Report? (Zacks)
06:20AM	Investing $15,000 Into Each of These 3 Growth Stocks 10 Years Ago Would Have Generated Over $3.8 Million in Profit Today (Motley Fool)
05:09AM	3 Reasons AXON Has Explosive Upside Potential (StockStory)
Mar-27-25 06:00PM	Axon Enterprise (AXON) Dips More Than Broader Market: What You Should Know (Zacks)
03:36PM	Axon Enterprise (AXON): Among Stocks to Trade Without Tariffs and Interest Rate Fears (InsiderMonkey)
11:49AM	Axon Enterprise Surges 39.9% in 6 Months: Should You Buy Now or Wait? (Zacks)
11:30AM	Axon (AXON) Down 2.3% Since Last Earnings Report: Can It Rebound? (Zacks)
11:15AM	Columbia Select Mid Cap Growth Fund Q4 2024 Commentary (SeekingAlpha)
Mar-26-25 02:55PM	Franklin Growth Opportunities Fund Q4 2024 Commentary (SeekingAlpha)
Mar-24-25 10:10AM	Here's Why You Should Retain Axon Enterprise Stock in Your Portfolio (Zacks)
09:30AM	BlackRock Mid-Cap Growth Equity Fund Q4 2024 Commentary (SeekingAlpha)
Mar-22-25 04:00AM	With the Nasdaq in Correction Territory, I've Got My Eye on These 2 Stocks (Motley Fool)
Mar-21-25 08:42AM	Word-of-Mouth Winners: 2 Stocks Growing Without Big Ad Budgets (MarketBeat)
06:14AM	If You Bought 1 Share of Axon Enterprise at Its IPO, Here's How Many Shares You Would Own Now (Motley Fool)
Mar-20-25 08:37AM	3 Defense Stocks Set to Benefit From Increased Military Spending (MarketBeat)
Mar-19-25 09:00AM	Axon Enterprise, Inc (AXON) Is a Trending Stock: Facts to Know Before Betting on It (Zacks) +5.21%
Mar-18-25 07:27AM	Is Axon Enterprise (AXON) One of the Best American Defense Stocks to Buy Now? (Insider Monkey)
Mar-17-25 06:00PM	Axon Enterprise (AXON) Stock Sinks As Market Gains: Here's Why (Zacks)
Mar-14-25 10:24AM	Energy Stocks Power S&P 500 Upside; Amazon, Google Make Nuclear Pledge (Investor's Business Daily)
Mar-13-25 10:16AM	Amid The Tumble, 3 Energy Stocks Lead The S&P 500 Upside (Investor's Business Daily)
Mar-12-25 11:28AM	Axon Enterprise, Inc. (AXON): Among Tech News Updates Investors Should Not Miss (Insider Monkey) +5.93%
Mar-10-25 09:48AM	Is Axon Enterprise, Inc. (AXON) the Best Defense Stock to Buy According to Billionaires? (Insider Monkey)
Mar-09-25 04:44PM	Jim Cramer On Axon Enterprise, Inc. (AXON): From TASER to Body Cameras One of the Best Conference Calls Ive Heard (Insider Monkey)
Mar-08-25 08:25AM	Axon Enterprise, Inc. (AXON) Growth Is Shockingly Strong, Says Jim Cramer (Insider Monkey)
Mar-07-25 11:22AM	Axon Enterprise, Inc. (AXON): A Bull Case Theory (Insider Monkey) +5.43%
07:00AM	AXON ANNOUNCES PRIVATE EXCHANGES OF CONVERTIBLE SENIOR NOTES (PR Newswire)
Mar-05-25 04:20PM	AXON ANNOUNCES PRICING OF UPSIZED OFFERING OF $1,000.0 MILLION OF 6.125% SENIOR NOTES DUE 2030 AND $750.0 MILLION OF 6.250% SENIOR NOTES DUE 2033 (PR Newswire) -6.66%
09:00AM	Investors Heavily Search Axon Enterprise, Inc (AXON): Here is What You Need to Know (Zacks)
07:11AM	AXON ANNOUNCES PROPOSED OFFERING OF $1,500.0 MILLION OF SENIOR NOTES (PR Newswire)
06:25AM	Why Axon Enterprise, Inc. (AXON) Is Gaining This Week (Insider Monkey)
03:24AM	Why Axon Enterprise Stock Fell in February (Motley Fool)
01:00AM	Nervous bosses to use Tasers for protection after UnitedHealthcare assassination (The Telegraph)
Mar-03-25 08:05PM	TD Cowen Raises Axon Enterprise, Inc. (AXON) Price Target to $725 on Strong Growth and AI Expansion (Insider Monkey)
Mar-02-25 09:00PM	Is Axon Enterprise Stock a Buy, Sell, or Hold in 2025? (Motley Fool)
Mar-01-25 04:35AM	3 Reasons to Buy Axon Enterprise Stock Now (Motley Fool)
Feb-27-25 02:22PM	Why Axon Enterprise Stock Is Sinking Today (Motley Fool) -8.20%
Feb-26-25 09:23PM	Axon Enterprise CEO Rick Smith sits down with Jim Cramer (CNBC TV) +15.25%
09:23PM	Axon Enterprise CEO on integrating AI into law enforcement (CNBC TV)
04:09PM	Stock Market Today: Dow Jones Falls As Nvidia Earnings Loom; AI Stock Jumps On Data Center Deal (Live Coverage) (Investor's Business Daily)
02:27PM	Nvidia, healthcare stocks, Axon: Market Minute (Yahoo Finance Video)
02:04PM	Why Axon Enterprise (AXON) Is Surging Today (Insider Monkey)
01:40PM	Taser Maker Axon Enterprise's Stock Soars on Strong Earnings, Outlook (Investopedia)
12:41PM	Why Axon Enterprise Stock Jumped Higher Today (Motley Fool)
10:34AM	Taser Maker Axon Reports Fourth-Quarter Earnings Beat. The Stock Jumps. (Barrons.com)
10:00AM	Q4 2024 Axon Enterprise Inc Earnings Call (Thomson Reuters StreetEvents)
09:15AM	Axon's 4th Quarter Checks All the Boxes (Motley Fool)
06:40AM	Axon Earnings: Taser Maker's Stunning News Revives Stock (Investor's Business Daily)

Axon Enterprise, Inc. engages in the development, manufacture, and sale of conducted electrical weapons for personal defense. It operates through the TASER segment and Software and Sensors segment. The TASER segment sells conducted electrical weapons, accessories, and other related products and services. The Software and Sensors segment includes devices, wearables, applications, cloud, and mobile products. The company was founded by Patrick W. Smith and Thomas P. Smith on September 7, 1993 and is headquartered in Scottsdale, AZ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Apr 21 '25	Sale	540.99	10,000	5,409,861	3,063,982	Apr 23 04:42 PM
SMITH PATRICK W	Officer	Apr 21 '25	Proposed Sale	550.00	10,000	5,500,000		Apr 21 04:25 PM
Williams Jeri	Director	Mar 17 '25	Sale	552.72	307	169,685	1,627	Mar 18 07:58 PM
JERI L WILLIAMS	Director	Mar 17 '25	Proposed Sale	556.26	307	170,772		Mar 17 04:33 PM
Kalinowski Caitlin Elizabeth	Director	Jan 02 '25	Sale	604.07	450	271,832	6,929	Jan 02 05:52 PM
CAITLIN KALINOWSKI	Director	Jan 02 '25	Proposed Sale	594.32	450	267,444		Jan 02 04:28 PM
Kunins Jeffrey C	CPO & CTO	Dec 23 '24	Sale	624.47	1,035	646,329	124,243	Dec 26 04:20 PM
JEFFREY C KUNINS	Officer	Dec 23 '24	Proposed Sale	631.69	1,035	653,799		Dec 23 04:22 PM
Isner Joshua	PRESIDENT	Dec 17 '24	Sale	642.43	1,291	829,375	181,892	Dec 17 06:52 PM
Kunins Jeffrey C	CPO & CTO	Dec 17 '24	Sale	639.14	1,370	875,623	125,950	Dec 17 06:50 PM
JEFFREY C KUNINS	Officer	Dec 17 '24	Proposed Sale	649.30	1,370	889,541		Dec 17 04:28 PM
Isner Joshua	Officer	Dec 17 '24	Proposed Sale	642.43	1,291	829,375		Dec 17 12:35 PM
GARNREITER MICHAEL	Director	Dec 16 '24	Sale	639.69	1,000	639,687	24,259	Dec 16 06:07 PM
THE GARNREITER FAMILY TRUST U/	Director	Dec 16 '24	Proposed Sale	644.91	1,000	644,910		Dec 16 04:32 PM
Cullivan Julie A	Director	Dec 04 '24	Sale	682.06	1,261	860,077	2,392	Dec 05 05:09 PM
Kunins Jeffrey C	CPO & CTO	Dec 03 '24	Sale	654.79	2,304	1,508,628	128,542	Dec 04 05:19 PM
Kunins Jeffrey C	CPO & CTO	Dec 04 '24	Sale	667.09	333	222,141	128,209	Dec 04 05:19 PM
Cullivan Julie A	Director	Dec 04 '24	Proposed Sale	682.06	1,261	860,077		Dec 04 04:51 PM
Isner Joshua	PRESIDENT	Dec 03 '24	Sale	647.38	2,258	1,461,782	184,987	Dec 04 04:48 PM
Isner Joshua	PRESIDENT	Dec 04 '24	Sale	667.09	836	557,687	184,151	Dec 04 04:48 PM
JEFFREY C KUNINS	Officer	Dec 04 '24	Proposed Sale	669.87	333	223,067		Dec 04 04:37 PM
Isner Joshua	Officer	Dec 04 '24	Proposed Sale	667.09	836	557,687		Dec 04 11:38 AM
JEFFREY C KUNINS	Officer	Dec 03 '24	Proposed Sale	636.39	2,304	1,466,243		Dec 03 04:32 PM
Isner Joshua	Officer	Dec 03 '24	Proposed Sale	647.38	2,258	1,461,782		Dec 03 12:39 PM
Bagley Brittany	COO & CFO	Nov 22 '24	Sale	640.00	3,500	2,240,000	76,635	Nov 25 04:55 PM
Isner Joshua	PRESIDENT	Nov 21 '24	Sale	635.06	9,600	6,096,539	189,567	Nov 25 04:47 PM
BRITTANY BAGLEY	Officer	Nov 22 '24	Proposed Sale	640.00	3,500	2,240,000		Nov 22 04:24 PM
Isner Joshua	Officer	Nov 21 '24	Proposed Sale	635.06	9,600	6,096,539		Nov 21 01:49 PM
MCBRADY MATTHEW R	Director	Nov 20 '24	Sale	605.20	1,000	605,196	3,892	Nov 20 04:29 PM
Matthew McBrady	Director	Nov 20 '24	Proposed Sale	610.35	1,000	610,350		Nov 20 12:38 PM
Bagley Brittany	COO & CFO	Nov 15 '24	Sale	598.75	6,325	3,787,070	80,135	Nov 19 04:35 PM
GARNREITER MICHAEL	Director	Nov 15 '24	Sale	599.53	1,000	599,530	25,259	Nov 19 04:33 PM
BRITTANY BAGLEY	Officer	Nov 15 '24	Proposed Sale	604.56	6,325	3,823,842		Nov 15 04:40 PM
Kunins Jeffrey C	CPO & CTO	Nov 13 '24	Sale	609.27	21,834	13,302,895	132,560	Nov 14 04:55 PM
Kunins Jeffrey C	CPO & CTO	Nov 12 '24	Sale	593.88	21,834	12,966,791	154,394	Nov 14 04:55 PM
Isner Joshua	PRESIDENT	Nov 12 '24	Sale	606.15	20,000	12,123,060	208,166	Nov 13 04:57 PM
JEFFREY C KUNINS	Officer	Nov 13 '24	Proposed Sale	609.27	21,834	13,302,895		Nov 13 04:22 PM
JEFFREY C KUNINS	Officer	Nov 12 '24	Proposed Sale	593.88	21,834	12,966,791		Nov 12 04:32 PM
Isner Joshua	Officer	Nov 12 '24	Proposed Sale	606.11	20,000	12,122,117		Nov 12 11:09 AM
GARNREITER MICHAEL	Director	Oct 15 '24	Sale	437.98	1,000	437,980	26,259	Oct 16 04:23 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Oct 03 '24	Sale	404.14	4,767	1,926,545	2,925,060	Oct 04 04:26 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Option Exercise	399.22	100,917	40,288,085	3,031,116	Oct 02 08:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Oct 02 '24	Option Exercise	404.51	58,965	23,851,932	3,042,767	Oct 02 08:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Sep 30 '24	Option Exercise	399.60	10,118	4,043,153	2,935	Oct 02 08:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Oct 02 '24	Sale	402.99	112,940	45,513,920	2,929,827	Oct 02 08:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Oct 01 '24	Sale	400.07	47,314	18,928,997	2,983,802	Oct 02 08:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Sep 30 '24	Sale	400.02	4,746	1,898,515	2,930,199	Oct 02 08:27 PM
PATRICK SMITH	Director	Oct 02 '24	Proposed Sale	399.22	117,707	46,990,989		Oct 02 06:53 PM
Williams Jeri	Director	Sep 30 '24	Sale	400.00	110	44,000	1,934	Oct 01 05:02 PM
PATRICK SMITH	Director	Oct 01 '24	Proposed Sale	399.60	47,314	18,906,674		Oct 01 04:37 PM
PATRICK SMITH	Director	Sep 30 '24	Proposed Sale	395.34	4,746	1,876,284		Sep 30 04:28 PM
JERI L WILLIAMS	Director	Sep 30 '24	Proposed Sale	395.34	110	43,487		Sep 30 04:27 PM
GARNREITER MICHAEL	Director	Sep 16 '24	Sale	380.99	1,000	380,990	27,259	Sep 17 04:58 PM
Bagley Brittany	COO & CFO	Sep 12 '24	Sale	378.95	4,338	1,643,876	98,825	Sep 12 05:15 PM
BRITTANY BAGLEY	Officer	Sep 12 '24	Proposed Sale	378.95	4,338	1,643,876		Sep 12 04:04 PM
Isner Joshua	PRESIDENT	Sep 10 '24	Sale	359.84	25,811	9,287,936	228,166	Sep 10 07:24 PM
Kunins Jeffrey C	CPO & CTO	Sep 09 '24	Sale	364.86	8,182	2,985,294	176,228	Sep 10 06:01 PM
Isner Joshua	Officer	Sep 10 '24	Proposed Sale	360.55	5,874	2,117,897		Sep 10 05:13 PM
Isner Joshua	Officer	Sep 10 '24	Proposed Sale	359.63	19,937	7,170,039		Sep 10 04:57 PM
JEFFREY C KUNINS	Officer	Sep 09 '24	Proposed Sale	354.62	8,182	2,901,501		Sep 09 04:32 PM
Cullivan Julie A	Director	Sep 05 '24	Sale	353.53	900	318,177	3,653	Sep 06 04:38 PM
JULIE ANNE CULLIVAN	Director	Sep 05 '24	Proposed Sale	355.35	900	319,815		Sep 05 04:27 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 30 '24	Option Exercise	364.97	105,495	38,502,510	3,030,861	Sep 04 05:51 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Sep 03 '24	Option Exercise	355.16	64,505	22,909,596	3,045,366	Sep 04 05:51 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Sep 03 '24	Sale	356.53	75,000	26,739,978	2,970,366	Sep 04 05:51 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 30 '24	Sale	364.02	50,000	18,201,051	2,980,861	Sep 04 05:51 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Sep 04 '24	Sale	352.57	45,539	16,055,756	2,924,827	Sep 04 05:51 PM
PATRICK W SMITH	Director	Sep 04 '24	Proposed Sale	355.16	2,539	901,751		Sep 04 04:19 PM
PATRICK W SMITH	Director	Aug 30 '24	Proposed Sale	362.00	168,000	60,816,000		Aug 30 04:36 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Option Exercise	370.70	170,000	63,019,000	3,095,666	Aug 27 05:26 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 23 '24	Sale	371.78	80,300	29,854,273	3,015,366	Aug 27 05:26 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 26 '24	Sale	362.21	70,000	25,354,817	2,945,366	Aug 27 05:26 PM
SMITH PATRICK W	CHIEF EXECUTIVE OFFICER	Aug 27 '24	Sale	362.21	20,000	7,244,146	2,925,366	Aug 27 05:26 PM
Williams Jeri	Director	Aug 22 '24	Sale	375.94	220	82,707	2,044	Aug 23 04:30 PM
PATRICK W SMITH	Director	Aug 23 '24	Proposed Sale	372.69	170,300	63,469,107		Aug 23 04:28 PM
Kalinowski Caitlin Elizabeth	Director	Aug 21 '24	Sale	373.03	450	167,864	7,379	Aug 22 04:38 PM
JERI L WILLIAMS	Director	Aug 22 '24	Proposed Sale	375.10	220	82,522		Aug 22 04:24 PM
CAITLIN KALINOWSKI	Director	Aug 21 '24	Proposed Sale	373.03	450	167,864		Aug 21 04:07 PM
GARNREITER MICHAEL	Director	Aug 16 '24	Sale	374.99	1,000	374,990	29,259	Aug 19 04:40 PM
Bagley Brittany	COO & CFO	Aug 15 '24	Sale	374.32	2,017	755,005	108,205	Aug 16 04:41 PM
THE GARNREITER FAMILY TRUSTU/A	Director	Aug 16 '24	Proposed Sale	373.69	4,000	1,494,760		Aug 16 04:26 PM
BRITTANY BAGLEY	Officer	Aug 15 '24	Proposed Sale	370.57	2,017	747,440		Aug 15 04:31 PM
MCBRADY MATTHEW R	Director	Aug 09 '24	Sale	364.66	2,000	729,328	4,892	Aug 12 04:26 PM
Matthew Mcbrady	Director	Aug 09 '24	Proposed Sale	365.00	2,000	730,000		Aug 09 03:28 PM
Isner Joshua	PRESIDENT	Jun 18 '24	Sale	297.78	1,434	427,016	273,332	Jun 20 04:42 PM
Cullivan Julie A	Director	May 31 '24	Sale	281.72	993	279,748	4,553	Jun 03 07:23 PM
Cullivan Julie A	Director	May 28 '24	Sale	286.04	478	136,727	5,546	May 29 04:37 PM
Kalinowski Caitlin Elizabeth	Director	May 20 '24	Sale	290.19	2,000	580,387	7,829	May 21 04:20 PM
Williams Jeri	Director	May 09 '24	Sale	310.07	308	95,501	1,607	May 13 05:51 PM
Kunins Jeffrey C	CPO & CTO	May 09 '24	Sale	309.94	43,668	13,534,282	189,719	May 13 05:48 PM
Isner Joshua	PRESIDENT	May 09 '24	Sale	309.96	44,000	13,638,357	275,843	May 13 05:45 PM

Dollar change -0.03
Percentage change -1.03	%

OCX Oncocyte Corporation daily Stock Chart

Peers: EXAS CDNA GH FLGT ILMN MYGN BNTX RCKT CRSP TXG

| Held by: VTI VXF IWC

Index	-	P/E	-	EPS (ttm)	-4.40	Insider Own	29.84%	Shs Outstand	28.60M	Perf Week	-7.37%
Market Cap	82.65M	Forward P/E	-	EPS next Y	-0.89	Insider Trans	316.41%	Shs Float	20.06M	Perf Month	4.33%
Income	-60.93M	PEG	-	EPS next Q	-0.24	Inst Own	48.10%	Short Float	2.01%	Perf Quarter	35.68%
Sales	1.88M	P/S	43.96	EPS this Y	80.71%	Inst Trans	5.26%	Short Ratio	5.02	Perf Half Y	-4.62%
Book/sh	-0.70	P/B	-	EPS next Y	1.51%	ROA	-110.32%	Short Interest	0.40M	Perf Year	13.33%
Cash/sh	0.30	P/C	9.57	EPS next 5Y	44.67%	ROE	-910.86%	52W Range	1.92 - 4.75	Perf YTD	21.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	11.82%	ROI	-	52W High	-39.16%	Beta	0.95
Dividend TTM	-	Quick Ratio	1.52	Sales past 5Y	21.28%	Gross Margin	-42.05%	52W Low	50.36%	ATR (14)	0.28
Dividend Ex-Date	-	Current Ratio	1.58	EPS Y/Y TTM	81.47%	Oper. Margin	-1235.89%	RSI (14)	44.08	Volatility	9.21% 8.39%
Employees	49	Debt/Eq	-	Sales Y/Y TTM	25.15%	Profit Margin	-3239.02%	Recom	2.00	Target Price	4.42
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	1.66%	Payout	-	Rel Volume	1.76	Prev Close	2.92
Sales Surprise	1361.16%	EPS Surprise	-382.50%	Sales Q/Q	373.25%	Earnings	Mar 24 AMC	Avg Volume	80.28K	Price	2.89
SMA20	-3.30%	SMA50	-8.58%	SMA200	1.67%	Trades		Volume	141,220	Change	-1.03%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-28-25	Initiated	Lake Street	Buy	$5
May-24-22	Downgrade	Stephens	Overweight → Equal-Weight
Mar-14-22	Downgrade	KeyBanc Capital Markets	Overweight → Sector Weight
Jan-07-22	Initiated	Stephens	Overweight	$3.10
Jan-06-22	Resumed	Piper Sandler	Overweight	$3.10
Mar-17-21	Resumed	Needham	Buy	$8
Jan-07-21	Upgrade	The Benchmark Company	Speculative Buy → Buy	$6
Dec-16-20	Upgrade	Piper Sandler	Neutral → Overweight	$2 → $4
Nov-30-20	Initiated	BTIG Research	Buy	$5
Nov-10-20	Initiated	KeyBanc Capital Markets	Overweight	$5
Jul-30-20	Reiterated	The Benchmark Company	Speculative Buy	$7 → $6
Jul-01-20	Downgrade	Piper Sandler	Overweight → Neutral
Jun-30-20	Downgrade	Chardan Capital Markets	Buy → Neutral	$2
Jun-02-20	Initiated	Needham	Buy	$4
Feb-13-19	Initiated	Piper Jaffray	Overweight	$6
Jan-29-19	Upgrade	Janney	Neutral → Buy
Dec-19-18	Resumed	Lake Street	Buy

Show Previous Ratings

Today 10:00AM	Best Momentum Stocks to Buy for May 6th (Zacks)
07:41AM	New Strong Buy Stocks for May 6th (Zacks)
Apr-30-25 08:30AM	Oncocyte Provides Positive Update on Clinical Trial Progress (GlobeNewswire)
Apr-29-25 08:30AM	Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity (GlobeNewswire)
Apr-24-25 05:00PM	STAAR Surgical Announces Changes to Board of Directors (Business Wire) +14.92%
06:31AM	Loading…
06:31AM	New Strong Buy Stocks for April 24th (Zacks)
Apr-07-25 12:00PM	OncoCyte (OCX) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Apr-02-25 08:45AM	Oncocyte to Participate in 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-24-25 06:53PM	OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript (SeekingAlpha) -8.71%
04:05PM	Oncocyte Reports Successful 2024; Sets Stage for 2025 Catalysts (GlobeNewswire)
Mar-18-25 04:05PM	Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025 (GlobeNewswire)
Feb-21-25 12:20AM	OncoCyte Corporation (OCX): Among Cheapest Stocks Insiders Are Buying Recently (Insider Monkey)
Feb-11-25 08:46AM	OncoCyte prices $29.1M equity offering (TipRanks) +14.49%
08:30AM	Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference (GlobeNewswire)
Feb-10-25 08:30AM	Oncocyte Prices $29.1 Million Equity Offering (GlobeNewswire)
08:30AM	Loading…
Jan-08-25 08:30AM	Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer (GlobeNewswire)
Jan-06-25 04:05PM	Oncocyte Expands Market Opportunity for VitaGraft Kidney (GlobeNewswire)
Dec-09-24 04:05PM	Oncocyte to Participate in J.P. Morgan Week and Host Investor Meetings (GlobeNewswire)
Dec-04-24 04:15PM	Oncocyte Demonstrates Potential for Liquid Biopsy of Brain Tumors in New Study (GlobeNewswire)
Dec-02-24 04:05PM	Oncocyte dd-cfDNA Assay Detects Kidney Transplant Rejection 11+ Months Ahead of Standard Protocols, New Study Affirms (GlobeNewswire)
Nov-13-24 02:21AM	OncoCyte Corp (OCX) Q3 2024 Earnings Call Highlights: Progress in Transplant Testing and ... (GuruFocus.com)
Nov-12-24 04:05PM	Oncocyte Reports Commercial Launch Progress; On Track to Sign 20 Transplant Centers by End of 2025 (GlobeNewswire)
Nov-06-24 04:45PM	Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12 (GlobeNewswire)
Oct-16-24 04:15PM	Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles (GlobeNewswire)
Oct-08-24 08:30AM	Oncocyte's DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial (GlobeNewswire)
Oct-04-24 06:28AM	OncoCyte Secures Funding Through Private Share Sale (TipRanks)
Oct-02-24 06:41PM	Oncocyte Signs Leading Transplant Centers in US and Germany (GlobeNewswire)
06:35PM	Oncocyte Corporation Announces $10.2 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
Aug-20-24 09:00AM	PRISM MarketView Features Oncocyte CFO Andrea S. James on Her Career and Leadership in Molecular Diagnostics Technology (GlobeNewswire)
Aug-12-24 04:10PM	Oncocyte's VitaGraft Kidney Used to Monitor Effect of Daratumumab on Anti-body Mediated Rejection in New Case Series Study (GlobeNewswire) -5.13%
04:05PM	Loading…
Aug-08-24 04:05PM	Oncocyte Announces Successful GraftAssure Beta Launch and Q2 2024 Results (GlobeNewswire)
Aug-05-24 04:05PM	Oncocyte Announces August Investor Conferences Participation (GlobeNewswire) +6.27%
Aug-01-24 04:05PM	Oncocyte to Announce Second Quarter 2024 Financial Results on August 8 (GlobeNewswire) -5.14%
Jul-11-24 08:00AM	MedTech Gurus Podcast Features Oncocyte CEO Josh Riggs in 'Take Advantage of the Moment' Episode (GlobeNewswire)
Jun-24-24 12:41PM	Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move (GlobeNewswire) -6.36%
Jun-17-24 04:05PM	Oncocyte Appoints Andrea James as Chief Financial Officer (GlobeNewswire)
Jun-05-24 07:00AM	OncoCyte's Innovative Approach: Potential in Precision Diagnostics (News Direct)
Jun-03-24 02:13PM	Breakthrough in Kidney Transplant Monitoring: PRISM MarketView Spotlights Oncocyte's VitaGraft Study (GlobeNewswire)
May-30-24 04:47PM	Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine (GlobeNewswire)
May-15-24 08:55PM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Oncocyte Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-13-24 08:00AM	Oncocyte to Announce First Quarter 2024 Financial Results (GlobeNewswire)
May-07-24 09:19AM	PRISM MarketView Spotlights Oncocyte Corporation as it Works to Disrupt the Precision Diagnostics Marketplace (GlobeNewswire)
Apr-12-24 10:52AM	OCX Stock Earnings: OncoCyte Misses EPS, Misses Revenue for Q4 2023 (InvestorPlace) -8.60%
06:00AM	Oncocyte Reports Full Year 2023 Financial Results (GlobeNewswire)
Apr-11-24 09:46PM	Oncocyte Corporation Announces $15.8 Million Private Placement of Securities Priced At-The-Market Under Nasdaq Rules (GlobeNewswire)
05:30PM	Oncocyte and Bio-Rad Partner on Global Launch of Transplant Assay (GlobeNewswire)
Apr-09-24 04:05PM	Oncocyte to Announce Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Jan-16-24 08:00AM	Oncocyte to Present at the Sequire Investor Summit in Puerto Rico (GlobeNewswire)
Dec-06-23 08:00AM	Oncocyte Begins FDA Submissions Process for VitaGraft Transplant Assays (GlobeNewswire)
Nov-09-23 08:27AM	OncoCyte Corp (OCX) Reports Q3 2023 Financial Results with Key Product Launches on the Horizon (GuruFocus.com) +29.71%
07:00AM	Oncocyte Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-03-23 08:30AM	Oncocyte to Announce Third Quarter 2023 Financial Results (GlobeNewswire) +8.09%
Sep-18-23 08:00AM	Oncocyte's VitaGraftTM Kidney Identifies Transplant Rejection 10 Months Earlier (ACCESSWIRE) +5.49%
Sep-06-23 08:00AM	Oncocyte to Participate in the H.C. Wainwright 25th Annual Global Investment Conference (ACCESSWIRE)
Aug-28-23 08:30AM	Oncocyte's VitaGraft Kidney Transplant Diagnostic Test Receives CMS Coverage (ACCESSWIRE)
Aug-10-23 07:00AM	Oncocyte Reports Second Quarter 2023 Financial Results (ACCESSWIRE)
Aug-09-23 08:00AM	Oncocyte Regains Compliance With Nasdaq Listing Requirements (ACCESSWIRE)
Aug-08-23 08:30AM	Oncocyte to Participate in 8th Annual Needham Virtual MedTech & Diagnostics 1×1 Conference (ACCESSWIRE) -5.29%
Aug-03-23 08:00AM	Oncocyte To Announce Second Quarter 2023 Financial Results (ACCESSWIRE)
Jul-25-23 09:08AM	VitaGraft Kidney Expands Utility in Recurrent Primary Disease Patients (GlobeNewswire)
Jul-24-23 01:35PM	Oncocyte Announces 1-For-20 Reverse Stock Split (GlobeNewswire) -9.57%
Jun-27-23 08:30AM	Oncocyte Begins Manufacturing Transplant Blood Test (GlobeNewswire)
Jun-01-23 04:15PM	Oncocyte Corporation to Present at the LD Micro Invitational XIII (Newsfile) +6.55%
May-11-23 08:00AM	Oncocyte Reports First Quarter 2023 Financial Results (GlobeNewswire)
Apr-27-23 04:59PM	Oncocyte To Announce First Quarter 2023 Financial Results (GlobeNewswire) +9.86%
Apr-18-23 08:45AM	Oncocyte Presents New Data at AACR (GlobeNewswire)
Apr-12-23 04:15PM	Oncocyte Announces Reduction in Force (GlobeNewswire) -5.08%
Apr-07-23 08:24AM	Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer (GlobeNewswire)
Apr-03-23 08:00AM	Oncocyte Pricing of $13.86 Million Public Offering of Common Stock (GlobeNewswire) -10.41%
Mar-31-23 05:00PM	Oncocyte Reports Preliminary Fourth Quarter and Full Year 2022 Financial Results and Plans to File Form 12b-25 to Extend Filing Date of Its Form 10-K (GlobeNewswire) +26.57%
Mar-29-23 04:01PM	Oncocyte Announces Date Change for Fourth Quarter and Full Year 2022 Earnings Call (GlobeNewswire) +5.52% -8.50%
Mar-15-23 04:01PM	Oncocyte to Announce Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) -20.00% +51.50%
Mar-02-23 09:00AM	Oncocyte Appoints Joshua Riggs as President and Chief Executive Officer (GlobeNewswire)
Feb-22-23 08:00AM	Oncocyte Completes Razor Genomics Transaction (GlobeNewswire)
Dec-16-22 08:19AM	Oncocyte cuts 40% of staff (MarketWatch) -21.95%
08:00AM	Oncocyte Announces Initiatives to Focus Corporate Strategy (GlobeNewswire)
Nov-30-22 06:05PM	Oncocyte Announces the Appointment of Louis E. Silverman as a Member of Its Board of Directors (GlobeNewswire)
06:00PM	Oncocyte Announces Executive Leadership Changes (GlobeNewswire)
Nov-10-22 04:30PM	Oncocyte Reports Third Quarter 2022 Financial Results (GlobeNewswire) -21.72%
Oct-27-22 04:01PM	Oncocyte to Announce Third Quarter 2022 Financial Results (GlobeNewswire) -13.50%
Oct-06-22 08:00AM	DetermaIO Clinical Test to be used in SWOG Cancer Research Network Biomarker Study for Breast Cancer (GlobeNewswire)
Sep-07-22 08:00AM	Oncocyte Announces Unanimous Recommendation from the Advisory Panel for Clinical Diagnostic Laboratory Tests on DetermaRx to CMS (GlobeNewswire)
Aug-31-22 04:01PM	Oncocyte to Participate at the Lake Street 6th Annual Best Ideas Growth Conference (GlobeNewswire)
Aug-30-22 04:27PM	Oncocyte Announces Five-Year VA Contract for DetermaRx (GlobeNewswire) -6.93%
Aug-24-22 08:00AM	Oncocyte Announces Publication of the Validation of DetermaIO in Predicting Immune Therapy Response in Metastatic Bladder Cancer (GlobeNewswire)
Aug-10-22 04:05PM	Oncocyte Reports Second Quarter 2022 Financial Results (GlobeNewswire) +10.57%
Aug-03-22 04:01PM	Oncocyte to Participate at Upcoming Investor Conferences (GlobeNewswire) +13.60%
Aug-01-22 11:33AM	The past year for OncoCyte (NASDAQ:OCX) investors has not been profitable (Simply Wall St.)
05:00AM	Oncocyte Announces the Appointment of John Peter Gutfreund as Independent Member of Its Board of Directors Effective July 28, 2022 (GlobeNewswire)
Jul-27-22 04:01PM	Oncocyte to Announce Second Quarter 2022 Financial Results (GlobeNewswire)
Jul-13-22 08:00AM	Oncocyte Announces Market Entry and Early Adopter Program for Transplant Rejection Monitoring Business (GlobeNewswire) +5.75%
Jul-06-22 08:00AM	Oncocyte Presents DetermaIO Data in Podium Presentation at ESMO World Congress on Gastrointestinal Cancer 2022 (GlobeNewswire)
Jun-22-22 08:00AM	Oncocyte Hosting Key Opinion Webinar on the Role of DetermaIO and the Tumor Microenvironment in Clinical Practice (GlobeNewswire)
Jun-15-22 07:15AM	How Much Of OncoCyte Corporation (NASDAQ:OCX) Do Insiders Own? (Simply Wall St.)
May-26-22 05:00PM	Oncocyte Presents DetermaIO Data at ASCO 2022 Supporting the Tests Potential to Expand the Clinical Use of Immunotherapy (GlobeNewswire)
May-11-22 04:05PM	Oncocyte Reports First Quarter 2022 Financial Results (GlobeNewswire)
May-05-22 08:00AM	Oncocyte Completes Validation of TheraSure Transplant Monitor Test (GlobeNewswire)
Apr-28-22 04:01PM	Oncocyte to Announce First Quarter 2022 Financial Results (GlobeNewswire)
Apr-27-22 04:30PM	Oncocyte to Present New Data at ASCO 2022 Underpinning Pan-Cancer Clinical Utility of DetermaIO (GlobeNewswire)

OncoCyte Corp. is a molecular diagnostics company, which engages in the development and commercialization of diagnostic tests for the detection of cancer, including molecular diagnostic services to pharmaceutical customers. Its products include DetermaRx and DetermaIO. The firm also offers pharmaceutical services like multi-analyte test development and clinical trial services. The company was founded in September 2009 and is headquartered in Alameda, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
James Andrea S.	Chief Financial Officer	Feb 07 '25	Buy	2.05	97,561	200,000	151,231	Feb 11 07:00 PM
SMITH PATRICK W	10% Owner	Feb 07 '25	Buy	2.05	1,077,600	2,209,080	2,872,671	Feb 11 05:00 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Feb 06 '25	Buy	2.05	5,165,695	10,589,675	11,410,100	Feb 10 08:43 PM
SMITH PATRICK W	10% Owner	Jan 31 '25	Buy	2.01	890	1,789	1,795,046	Feb 04 04:45 PM
SMITH PATRICK W	10% Owner	Feb 04 '25	Buy	2.02	25	50	1,795,071	Feb 04 04:45 PM
SMITH PATRICK W	10% Owner	Jan 29 '25	Buy	2.01	3,880	7,799	1,793,838	Jan 31 05:00 PM
SMITH PATRICK W	10% Owner	Jan 30 '25	Buy	2.01	318	639	1,794,156	Jan 31 05:00 PM
SMITH PATRICK W	10% Owner	Jan 14 '25	Buy	2.15	10,386	22,323	1,789,958	Jan 15 05:00 PM
SMITH PATRICK W	10% Owner	Jan 13 '25	Buy	2.08	5,669	11,792	1,779,572	Jan 15 05:00 PM
SMITH PATRICK W	10% Owner	Dec 26 '24	Buy	2.13	90,219	192,166	1,773,903	Dec 27 09:49 PM
Arno Andrew	Director	Dec 26 '24	Buy	2.11	12,500	26,350	81,554	Dec 26 06:17 PM
James Andrea S.	Chief Financial Officer	Dec 05 '24	Buy	2.29	20,000	45,800	53,670	Dec 09 08:00 AM
James Andrea S.	Chief Financial Officer	Oct 02 '24	Buy	2.97	33,670	100,000	33,670	Oct 04 07:40 PM
BROADWOOD PARTNERS, L.P.	10% Owner	Oct 02 '24	Buy	2.95	1,315,339	3,877,619	6,244,405	Oct 04 07:00 PM

AXON

Axon Enterprise Inc

OCX

Oncocyte Corporation

Upgrade your FINVIZ experience